TY - JOUR AU - Burmeister, T. AU - Schwartz, S. AU - Bartram, C. R. AU - Gökbuget, N. AU - Hoelzer, D. AU - Thiel, E. PY - 2008 DA - 2008// TI - Patients’ age and BCR-ABL frequency in adult B-precursor ALL: a retrospective analysis from the GMALL study group JO - Blood VL - 112 UR - https://doi.org/10.1182/blood-2008-04-149286 DO - 10.1182/blood-2008-04-149286 ID - Burmeister2008 ER - TY - JOUR AU - Ward, H. W. PY - 1973 DA - 1973// TI - Anti-oestrogen therapy for breast cancer: a trial of tamoxifen at two dose levels JO - Br Med J VL - 1 UR - https://doi.org/10.1136/bmj.1.5844.13 DO - 10.1136/bmj.1.5844.13 ID - Ward1973 ER - TY - JOUR AU - Druker, B. J. AU - Tamura, S. AU - Buchdunger, E. AU - Ohno, S. AU - Segal, G. M. AU - Fanning, S. PY - 1996 DA - 1996// TI - Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells JO - Nat Med VL - 2 UR - https://doi.org/10.1038/nm0596-561 DO - 10.1038/nm0596-561 ID - Druker1996 ER - TY - JOUR AU - Zimmermann, J. AU - Buchdunger, E. AU - Mett, H. AU - Meyer, T. AU - Lydon, N. B. PY - 1997 DA - 1997// TI - Potent and selective inhibitors of the Abl-kinase: phenylaminopyrimidine (PAP) derivatives JO - Bioorganic Med Chem Lett. VL - 7 UR - https://doi.org/10.1016/S0960-894X(96)00601-4 DO - 10.1016/S0960-894X(96)00601-4 ID - Zimmermann1997 ER - TY - JOUR AU - O’Brien, S. G. AU - Guilhot, F. AU - Larson, R. A. AU - Gathmann, I. AU - Baccarani, M. AU - Cervantes, F. PY - 2003 DA - 2003// TI - Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia JO - N Engl J Med VL - 348 UR - https://doi.org/10.1056/NEJMoa022457 DO - 10.1056/NEJMoa022457 ID - O’Brien2003 ER - TY - JOUR AU - Nicolini, F. E. AU - Mauro, M. J. AU - Martinelli, G. AU - Kim, D. -. W. AU - Soverini, S. AU - Müller, M. C. PY - 2009 DA - 2009// TI - Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation JO - Blood VL - 114 UR - https://doi.org/10.1182/blood-2009-04-219410 DO - 10.1182/blood-2009-04-219410 ID - Nicolini2009 ER - TY - JOUR AU - Jabbour, E. AU - Kantarjian, H. AU - Jones, D. AU - Breeden, M. AU - Garcia-Manero, G. AU - O’brien, S. PY - 2008 DA - 2008// TI - Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy JO - Blood VL - 112 UR - https://doi.org/10.1182/blood-2007-11-123950 DO - 10.1182/blood-2007-11-123950 ID - Jabbour2008 ER - TY - JOUR AU - Bradeen, H. A. AU - Eide, C. A. AU - O’Hare, T. AU - Johnson, K. J. AU - Willis, S. G. AU - Lee, F. Y. PY - 2006 DA - 2006// TI - Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2006-02-004580 DO - 10.1182/blood-2006-02-004580 ID - Bradeen2006 ER - TY - JOUR AU - Nicolini, F. E. AU - Basak, G. W. AU - Kim, D. W. AU - Olavarria, E. AU - Pinilla-Ibarz, J. AU - Apperley, J. F. PY - 2017 DA - 2017// TI - Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation JO - Cancer VL - 123 UR - https://doi.org/10.1002/cncr.30558 DO - 10.1002/cncr.30558 ID - Nicolini2017 ER - TY - JOUR AU - Wang, W. AU - Cortes, J. E. AU - Tang, G. AU - Khoury, J. D. AU - Wang, S. AU - Bueso-Ramos, C. E. PY - 2016 DA - 2016// TI - Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2016-01-690230 DO - 10.1182/blood-2016-01-690230 ID - Wang2016 ER - TY - JOUR AU - Reddy, E. P. AU - Aggarwal, A. K. PY - 2012 DA - 2012// TI - The ins and outs of Bcr-Abl inhibition JO - Genes and Cancer VL - 3 UR - https://doi.org/10.1177/1947601912462126 DO - 10.1177/1947601912462126 ID - Reddy2012 ER - TY - JOUR AU - Azam, M. AU - Seeliger, M. A. AU - Gray, N. S. AU - Kuriyan, J. AU - Daley, G. Q. PY - 2008 DA - 2008// TI - Activation of tyrosine kinases by mutation of the gatekeeper threonine JO - Nat Struct Mol Biol VL - 15 UR - https://doi.org/10.1038/nsmb.1486 DO - 10.1038/nsmb.1486 ID - Azam2008 ER - TY - JOUR AU - Schindler, T. PY - 2000 DA - 2000// TI - Structural mechanism for STI-571 inhibition of abelson tyrosine kinase JO - Science (80- ) VL - 289 UR - https://doi.org/10.1126/science.289.5486.1938 DO - 10.1126/science.289.5486.1938 ID - Schindler2000 ER - TY - JOUR AU - Capdeville, R. AU - Buchdunger, E. AU - Zimmermann, J. AU - Matter, A. PY - 2002 DA - 2002// TI - Glivec (ST1571, imatinib), a rationally developed, targeted anticancer drug JO - Nat Rev Drug Discov VL - 1 UR - https://doi.org/10.1038/nrd839 DO - 10.1038/nrd839 ID - Capdeville2002 ER - TY - JOUR AU - Buchdunger, E. AU - O’Reilly, T. AU - Wood, J. PY - 2002 DA - 2002// TI - Pharmacology of imatinib (STI571) JO - Eur J Cancer VL - 38 UR - https://doi.org/10.1016/S0959-8049(02)80600-1 DO - 10.1016/S0959-8049(02)80600-1 ID - Buchdunger2002 ER - TY - JOUR AU - Druker, B. J. AU - Lydon, N. B. PY - 2000 DA - 2000// TI - Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia JO - J Clin Invest VL - 105 UR - https://doi.org/10.1172/JCI9083 DO - 10.1172/JCI9083 ID - Druker2000 ER - TY - JOUR AU - Rix, U. AU - Hantschel, O. AU - Dürnberger, G. AU - Remsing Rix, L. L. AU - Planyavsky, M. AU - Fernbach, N. V. PY - 2007 DA - 2007// TI - Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets JO - Blood VL - 110 UR - https://doi.org/10.1182/blood-2007-07-102061 DO - 10.1182/blood-2007-07-102061 ID - Rix2007 ER - TY - JOUR AU - Hasford, J. AU - Baccarani, M. AU - Hoffmann, V. AU - Guilhot, J. AU - Saussele, S. AU - Rosti, G. PY - 2011 DA - 2011// TI - Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2010-12-319038 DO - 10.1182/blood-2010-12-319038 ID - Hasford2011 ER - TY - JOUR AU - Hochhaus, A. AU - Kreil, S. AU - Corbin, A. S. AU - La Rosée, P. AU - Müller, M. C. AU - Lahaye, T. PY - 2002 DA - 2002// TI - Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy JO - Leukemia VL - 16 UR - https://doi.org/10.1038/sj.leu.2402741 DO - 10.1038/sj.leu.2402741 ID - Hochhaus2002 ER - TY - JOUR AU - Weisberg, E. AU - Manley, P. W. AU - Breitenstein, W. AU - Brüggen, J. AU - Cowan-Jacob, S. W. AU - Ray, A. PY - 2005 DA - 2005// TI - Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl JO - Cancer Cell VL - 7 UR - https://doi.org/10.1016/j.ccr.2005.01.007 DO - 10.1016/j.ccr.2005.01.007 ID - Weisberg2005 ER - TY - JOUR AU - Hochhaus, A. AU - Saussele, S. AU - Rosti, G. AU - Mahon, F. -. X. AU - Janssen, J. J. W. M. AU - Hjorth-Hansen, H. PY - 2017 DA - 2017// TI - Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 28 UR - https://doi.org/10.1093/annonc/mdx219 DO - 10.1093/annonc/mdx219 ID - Hochhaus2017 ER - TY - CHAP AU - Hantschel, O. AU - Rix, U. AU - Superti-Furga, G. PY - 2008 DA - 2008// TI - Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib BT - Leukemia and Lymphoma ID - Hantschel2008 ER - TY - JOUR AU - Kantarjian, H. M. AU - Hochhaus, A. AU - Saglio, G. AU - De, S. C. AU - Flinn, I. W. AU - Stenke, L. PY - 2011 DA - 2011// TI - Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(11)70201-7 DO - 10.1016/S1470-2045(11)70201-7 ID - Kantarjian2011 ER - TY - JOUR AU - Davies, A. AU - Jordanides, N. E. AU - Giannoudis, A. AU - Lucas, C. M. AU - Hatziieremia, S. AU - Harris, R. J. PY - 2009 DA - 2009// TI - Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters JO - Leukemia VL - 23 UR - https://doi.org/10.1038/leu.2009.166 DO - 10.1038/leu.2009.166 ID - Davies2009 ER - TY - JOUR AU - Kantarjian, H. M. AU - Shah, N. P. AU - Cortes, J. E. AU - Baccarani, M. AU - Agarwal, M. B. AU - Undurraga, M. S. PY - 2012 DA - 2012// TI - Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION) JO - Blood VL - 119 UR - https://doi.org/10.1182/blood-2011-08-376087 DO - 10.1182/blood-2011-08-376087 ID - Kantarjian2012 ER - TY - STD TI - Skora L, Mestan J, Fabbro D, Jahnke W, Grzesiek S. NMR reveals the allosteric opening and closing of Abelson tyrosine kinase by ATP-site and myristoyl pocket inhibitors. Proc Natl Acad Sci. 2013;110:E4437–45. https://doi.org/10.1073/pnas.1314712110. ID - ref26 ER - TY - JOUR AU - Shah, N. P. AU - Tran, C. AU - Lee, F. Y. AU - Chen, P. AU - Norris, D. AU - Sawyers, C. L. PY - 2004 DA - 2004// TI - Overriding imatinib resistance with a novel ABL kinase inhibitor JO - Science VL - 305 UR - https://doi.org/10.1126/science.1099480 DO - 10.1126/science.1099480 ID - Shah2004 ER - TY - JOUR AU - Boschelli, D. H. AU - Ye, F. AU - Wang, Y. D. AU - Dutia, M. AU - Johnson, S. L. AU - Wu, B. PY - 2001 DA - 2001// TI - Optimization of 4-phenylamino-3-quinolinecarbonitriles as potent inhibitors of Src kinase activity JO - J Med Chem VL - 44 UR - https://doi.org/10.1021/jm0102250 DO - 10.1021/jm0102250 ID - Boschelli2001 ER - TY - JOUR AU - Boschelli, F. AU - Arndt, K. AU - Gambacorti-Passerini, C. PY - 2010 DA - 2010// TI - Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia JO - Eur J Cancer VL - 46 UR - https://doi.org/10.1016/j.ejca.2010.02.032 DO - 10.1016/j.ejca.2010.02.032 ID - Boschelli2010 ER - TY - JOUR AU - Redaelli, S. AU - Piazza, R. AU - Rostagno, R. AU - Magistroni, V. AU - Perini, P. AU - Marega, M. PY - 2009 DA - 2009// TI - Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.19.8853 DO - 10.1200/JCO.2008.19.8853 ID - Redaelli2009 ER - TY - STD TI - Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim D-W, et al. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2017:JCO2017747162. https://doi.org/10.1200/JCO.2017.74.7162. ID - ref31 ER - TY - JOUR AU - Zhou, T. AU - Commodore, L. AU - Huang, W. S. AU - Wang, Y. AU - Thomas, M. AU - Keats, J. PY - 2011 DA - 2011// TI - Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance JO - Chem Biol Drug Des VL - 77 UR - https://doi.org/10.1111/j.1747-0285.2010.01054.x DO - 10.1111/j.1747-0285.2010.01054.x ID - Zhou2011 ER - TY - JOUR AU - Huang, W. S. AU - Metcalf, C. A. AU - Sundaramoorthi, R. AU - Wang, Y. AU - Zou, D. AU - Thomas, R. M. PY - 2010 DA - 2010// TI - Discovery of 3-[2-(imidazo[1,2- b ]pyridazin-3-yl)ethynyl]-4-methyl- N -{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant JO - J Med Chem VL - 53 UR - https://doi.org/10.1021/jm100395q DO - 10.1021/jm100395q ID - Huang2010 ER - TY - JOUR AU - Cortes, J. E. AU - Kantarjian, H. AU - Shah, N. P. AU - Bixby, D. AU - Mauro, M. J. AU - Flinn, I. PY - 2012 DA - 2012// TI - Ponatinib in refractory Philadelphia chromosome–positive leukemias JO - N Engl J Med VL - 367 UR - https://doi.org/10.1056/NEJMoa1205127 DO - 10.1056/NEJMoa1205127 ID - Cortes2012 ER - TY - JOUR AU - Steegmann, J. L. AU - Baccarani, M. AU - Breccia, M. AU - Casado, L. F. AU - García-Gutiérrez, V. AU - Hochhaus, A. PY - 2016 DA - 2016// TI - European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia JO - Leukemia VL - 30 UR - https://doi.org/10.1038/leu.2016.104 DO - 10.1038/leu.2016.104 ID - Steegmann2016 ER - TY - JOUR AU - Kimura, S. AU - Naito, H. AU - Segawa, H. AU - Kuroda, J. AU - Yuasa, T. AU - Sato, K. PY - 2005 DA - 2005// TI - NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia JO - Blood VL - 106 UR - https://doi.org/10.1182/blood-2005-06-2209 DO - 10.1182/blood-2005-06-2209 ID - Kimura2005 ER - TY - JOUR AU - Lambert, G. K. AU - Duhme-Klair, A. K. AU - Morgan, T. AU - Ramjee, M. K. PY - 2013 DA - 2013// TI - The background, discovery and clinical development of BCR-ABL inhibitors JO - Drug Discov Today VL - 18 UR - https://doi.org/10.1016/j.drudis.2013.06.001 DO - 10.1016/j.drudis.2013.06.001 ID - Lambert2013 ER - TY - JOUR AU - Kantarjian, H. AU - Le Coutre, P. AU - Cortes, J. AU - Pinilla-Ibarz, J. AU - Nagler, A. AU - Hochhaus, A. PY - 2010 DA - 2010// TI - Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance JO - Cancer VL - 116 ID - Kantarjian2010 ER - TY - JOUR AU - Eide, C. A. AU - Adrian, L. T. AU - Tyner, J. W. AU - Mac, P. M. AU - David, J. AU - Wise, S. C. PY - 2011 DA - 2011// TI - ABL switch control inhibitor DCC 2036 active against CML mutant BCR ABL JO - Cancer Res VL - 71 UR - https://doi.org/10.1158/0008-5472.CAN-10-3224 DO - 10.1158/0008-5472.CAN-10-3224 ID - Eide2011 ER - TY - JOUR AU - Chan, W. W. AU - Wise, S. C. AU - Kaufman, M. D. AU - Ahn, Y. M. AU - Ensinger, C. L. AU - Haack, T. PY - 2011 DA - 2011// TI - Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036 JO - Cancer Cell VL - 19 UR - https://doi.org/10.1016/j.ccr.2011.03.003 DO - 10.1016/j.ccr.2011.03.003 ID - Chan2011 ER - TY - JOUR AU - Cortes, J. AU - Talpaz, M. AU - Smith, H. P. AU - Snyder, D. S. AU - Khoury, J. AU - Bhalla, K. N. PY - 2017 DA - 2017// TI - Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia JO - Haematologica VL - 102 UR - https://doi.org/10.3324/haematol.2016.152710 DO - 10.3324/haematol.2016.152710 ID - Cortes2017 ER - TY - JOUR AU - Bebbington, D. AU - Binch, H. AU - Charrier, J. D. AU - Everitt, S. AU - Fraysse, D. AU - Golec, J. PY - 2009 DA - 2009// TI - The discovery of the potent aurora inhibitor MK-0457 (VX-680) JO - Bioorganic Med Chem Lett. VL - 19 UR - https://doi.org/10.1016/j.bmcl.2009.04.136 DO - 10.1016/j.bmcl.2009.04.136 ID - Bebbington2009 ER - TY - JOUR AU - Young, M. A. AU - Shah, N. P. AU - Chao, L. H. AU - Seeliger, M. AU - Milanov, Z. V. AU - Biggs, W. H. PY - 2006 DA - 2006// TI - Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680 JO - Cancer Res VL - 66 UR - https://doi.org/10.1158/0008-5472.CAN-05-2788 DO - 10.1158/0008-5472.CAN-05-2788 ID - Young2006 ER - TY - JOUR AU - Giles, F. J. AU - Swords, R. T. AU - Nagler, A. AU - Hochhaus, A. AU - Ottmann, O. G. AU - Rizzieri, D. A. PY - 2013 DA - 2013// TI - MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia JO - Leukemia VL - 27 UR - https://doi.org/10.1038/leu.2012.186 DO - 10.1038/leu.2012.186 ID - Giles2013 ER - TY - CHAP AU - Gontarewicz, A. AU - Brümmendorf, T. H. PY - 2010 DA - 2010// TI - Danusertib (formerly PHA-739358)—a novel combined Pan-aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor BT - Small molecules in oncology PB - Springer Verlag CY - Berlin Heidelberg UR - https://doi.org/10.1007/978-3-642-01222-8_14 DO - 10.1007/978-3-642-01222-8_14 ID - Gontarewicz2010 ER - TY - JOUR AU - Meulenbeld, H. J. AU - Mathijssen, R. H. J. AU - Verweij, J. AU - de Wit, R. AU - de Jonge, M. J. PY - 2012 DA - 2012// TI - Danusertib, an aurora kinase inhibitor JO - Expert Opin Investig Drugs VL - 21 UR - https://doi.org/10.1517/13543784.2012.652303 DO - 10.1517/13543784.2012.652303 ID - Meulenbeld2012 ER - TY - JOUR AU - Modugno, M. AU - Casale, E. AU - Soncini, C. AU - Rosettani, P. AU - Colombo, R. AU - Lupi, R. PY - 2007 DA - 2007// TI - Crystal structure of the T315I Abl mutant in complex with the Aurora kinases inhibitor PHA-739358 JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-07-1825 DO - 10.1158/0008-5472.CAN-07-1825 ID - Modugno2007 ER - TY - JOUR AU - Gontarewicz, A. AU - Balabanov, S. AU - Keller, G. AU - Colombo, R. AU - Graziano, A. AU - Pesenti, E. PY - 2008 DA - 2008// TI - Simultaneous targeting of Aurora kinases and Bcr-Abl kinase by the small molecule inhibitor PHA-739358 is effective against imatinib-resistant BCR-ABL mutations including T315I JO - Blood VL - 111 UR - https://doi.org/10.1182/blood-2007-09-113175 DO - 10.1182/blood-2007-09-113175 ID - Gontarewicz2008 ER - TY - JOUR AU - Borthakur, G. AU - Dombret, H. AU - Schafhausen, P. AU - Brummendorf, T. H. AU - Boisse, N. AU - Jabbour, E. PY - 2015 DA - 2015// TI - A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generation c-ABL therapy JO - Haematologica VL - 100 UR - https://doi.org/10.3324/haematol.2014.115279 DO - 10.3324/haematol.2014.115279 ID - Borthakur2015 ER - TY - JOUR AU - Weisberg, E. AU - Choi, H. G. AU - Ray, A. AU - Barrett, R. AU - Zhang, J. AU - Sim, T. PY - 2010 DA - 2010// TI - Discovery of a small-molecule type II inhibitor of wild-type and gatekeeper mutants of BCR-ABL, PDGFRα, Kit, and Src kinases: novel type II inhibitor of gatekeeper mutants JO - Blood VL - 115 UR - https://doi.org/10.1182/blood-2009-11-251751 DO - 10.1182/blood-2009-11-251751 ID - Weisberg2010 ER - TY - JOUR AU - Karaman, M. W. AU - Herrgard, S. AU - Treiber, D. K. AU - Gallant, P. AU - Atteridge, C. E. AU - Campbell, B. T. PY - 2008 DA - 2008// TI - A quantitative analysis of kinase inhibitor selectivity JO - Nat Biotechnol VL - 26 UR - https://doi.org/10.1038/nbt1358 DO - 10.1038/nbt1358 ID - Karaman2008 ER - TY - JOUR AU - Zhang, J. AU - Adrian, F. J. AU - Jahnke, W. AU - Cowan-jacob, S. W. AU - Li, A. G. AU - Iacob, R. E. PY - 2010 DA - 2010// TI - Targeting wild-type and T315I Bcr-Abl by combining allosteric with ATP-site inhibitors JO - Nature VL - 463 UR - https://doi.org/10.1038/nature08675 DO - 10.1038/nature08675 ID - Zhang2010 ER - TY - JOUR AU - Khateb, M. AU - Ruimi, N. AU - Khamisie, H. AU - Najajreh, Y. AU - Mian, A. AU - Metodieva, A. PY - 2012 DA - 2012// TI - Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl-independent mechanism JO - BMC Cancer VL - 12 UR - https://doi.org/10.1186/1471-2407-12-563 DO - 10.1186/1471-2407-12-563 ID - Khateb2012 ER - TY - STD TI - Altıntop MD, Ciftci HI, Radwan MO, Otsuka M, Özdemir A. Design, synthesis, and biological evaluation of novel 1,3,4-thiadiazole derivatives as potential antitumor agents against chronic myelogenous leukemia: striking effect of nitrothiazole moiety. Molecules. 2018 https://doi.org/10.3390/molecules23010059. ID - ref54 ER - TY - JOUR AU - Jain, A. K. AU - Sharma, S. AU - Vaidya, A. AU - Ravichandran, V. AU - Agrawal, R. K. PY - 2013 DA - 2013// TI - 1,3,4-Thiadiazole and its derivatives: a review on recent progress in biological activities JO - Chem Biol Drug Des VL - 81 UR - https://doi.org/10.1111/cbdd.12125 DO - 10.1111/cbdd.12125 ID - Jain2013 ER - TY - JOUR AU - Kalmanti, L. AU - Saussele, S. AU - Lauseker, M. AU - Müller, M. C. AU - Dietz, C. T. AU - Heinrich, L. PY - 2015 DA - 2015// TI - Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV JO - Leukemia VL - 29 UR - https://doi.org/10.1038/leu.2015.36 DO - 10.1038/leu.2015.36 ID - Kalmanti2015 ER - TY - JOUR AU - Shah, N. P. AU - Nicoll, J. M. AU - Nagar, B. AU - Gorre, M. E. AU - Paquette, R. L. AU - Kuriyan, J. PY - 2002 DA - 2002// TI - Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia JO - Cancer Cell VL - 2 UR - https://doi.org/10.1016/S1535-6108(02)00096-X DO - 10.1016/S1535-6108(02)00096-X ID - Shah2002 ER - TY - JOUR AU - Yu, H. A. AU - Arcila, M. E. AU - Hellmann, M. D. AU - Kris, M. G. AU - Ladanyi, M. AU - Riely, G. J. PY - 2014 DA - 2014// TI - Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing JO - Ann Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdt573 DO - 10.1093/annonc/mdt573 ID - Yu2014 ER - TY - JOUR AU - Kim, S. AU - Kim, T. M. AU - Kim, D. W. AU - Go, H. AU - Keam, B. AU - Lee, S. H. PY - 2013 DA - 2013// TI - Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer JO - J Thorac Oncol VL - 8 UR - https://doi.org/10.1097/JTO.0b013e318283dcc0 DO - 10.1097/JTO.0b013e318283dcc0 ID - Kim2013 ER - TY - JOUR AU - Deininger, M. W. AU - Hodgson, J. G. AU - Shah, N. P. AU - Cortes, J. E. AU - Kim, D. W. AU - Nicolini, F. E. PY - 2016 DA - 2016// TI - Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients JO - Blood VL - 127 UR - https://doi.org/10.1182/blood-2015-08-660977 DO - 10.1182/blood-2015-08-660977 ID - Deininger2016 ER - TY - STD TI - Kavanagh S, Nee A, Lipton JH. Emerging alternatives to tyrosine kinase inhibitors for treating chronic myeloid leukemia. Expert Opin Emerg Drugs. 2018; https://doi.org/10.1080/14728214.2018.1445717. ID - ref61 ER - TY - JOUR AU - Vezzalini, M. AU - Mafficini, A. AU - Tomasello, L. AU - Lorenzetto, E. AU - Moratti, E. AU - Fiorini, Z. PY - 2017 DA - 2017// TI - A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients JO - J Hematol Oncol VL - 10 UR - https://doi.org/10.1186/s13045-017-0494-z DO - 10.1186/s13045-017-0494-z ID - Vezzalini2017 ER - TY - JOUR AU - Orciuolo, E. AU - Buda, G. AU - Galimberti, S. AU - Cervetti, G. AU - Cecconi, N. AU - Papineschi, F. PY - 2008 DA - 2008// TI - Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia JO - Leuk Res VL - 32 UR - https://doi.org/10.1016/j.leukres.2007.02.001 DO - 10.1016/j.leukres.2007.02.001 ID - Orciuolo2008 ER - TY - JOUR AU - Orciuolo, E. AU - Buda, G. AU - Galimberti, S. AU - Cecconi, N. AU - Cervetti, G. AU - Petrini, M. PY - 2008 DA - 2008// TI - Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia JO - Leuk Res VL - 32 UR - https://doi.org/10.1016/j.leukres.2007.01.017 DO - 10.1016/j.leukres.2007.01.017 ID - Orciuolo2008 ER - TY - JOUR AU - Ogbogu, P. U. AU - Bochner, B. S. AU - Butterfield, J. H. AU - Gleich, G. J. AU - Huss-Marp, J. AU - Kahn, J. E. PY - 2009 DA - 2009// TI - Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy JO - J Allergy Clin Immunol VL - 124 UR - https://doi.org/10.1016/j.jaci.2009.09.022 DO - 10.1016/j.jaci.2009.09.022 ID - Ogbogu2009 ER - TY - STD TI - Montemurro M, Cioffi A, Dômont J, Rutkowski P, Roth AD, von Moos R, et al. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: A multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). Cancer. 2018;124:1449–54. ID - ref66 ER - TY - JOUR AU - Chiarella, P. AU - Summa, V. AU - De Santis, S. AU - Signori, E. AU - Picardi, E. AU - Pesole, G. PY - 2012 DA - 2012// TI - BCR/ABL1 fusion transcripts generated from alternative splicing: implications for future targeted therapies in Ph+ leukaemias JO - Curr Mol Med VL - 12 UR - https://doi.org/10.2174/156652412800619996 DO - 10.2174/156652412800619996 ID - Chiarella2012 ER - TY - JOUR AU - Reckel, S. AU - Hamelin, R. AU - Georgeon, S. AU - Armand, F. AU - Jolliet, Q. AU - Chiappe, D. PY - 2017 DA - 2017// TI - Differential signaling networks of Bcr-Abl p210 and p190 kinases in leukemia cells defined by functional proteomics JO - Leukemia VL - 31 UR - https://doi.org/10.1038/leu.2017.36 DO - 10.1038/leu.2017.36 ID - Reckel2017 ER - TY - JOUR AU - Breccia, M. AU - Alimena, G. PY - 2014 DA - 2014// TI - Second-generation tyrosine kinase inhibitors (Tki) as salvage therapy for resistant or intolerant patients to prior TKIs JO - Mediterr J Hematol Infect Dis VL - 6 UR - https://doi.org/10.4084/mjhid.2014.003 DO - 10.4084/mjhid.2014.003 ID - Breccia2014 ER - TY - JOUR AU - Pan, J. AU - Quintás-Cardama, A. AU - Manshouri, T. AU - Cortes, J. AU - Kantarjian, H. AU - Verstovsek, S. PY - 2007 DA - 2007// TI - Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406 JO - Cancer Sci VL - 98 UR - https://doi.org/10.1111/j.1349-7006.2007.00516.x DO - 10.1111/j.1349-7006.2007.00516.x ID - Pan2007 ER - TY - JOUR AU - Weisberg, E. AU - Wright, R. D. AU - Jiang, J. AU - Ray, A. AU - Moreno, D. AU - Manley, P. W. PY - 2006 DA - 2006// TI - Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity JO - Gastroenterology VL - 131 UR - https://doi.org/10.1053/j.gastro.2006.09.017 DO - 10.1053/j.gastro.2006.09.017 ID - Weisberg2006 ER - TY - JOUR AU - Von Bubnoff, N. AU - Gorantla, S. P. AU - Thöne, S. AU - Peschel, C. AU - Duyster, J. PY - 2006 DA - 2006// TI - The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib) JO - Blood VL - 107 UR - https://doi.org/10.1182/blood-2006-01-0285 DO - 10.1182/blood-2006-01-0285 ID - Von Bubnoff2006 ER - TY - JOUR AU - Duveau, D. Y. AU - Hu, X. AU - Walsh, M. J. AU - Shukla, S. AU - Skoumbourdis, A. P. AU - Boxer, M. B. PY - 2013 DA - 2013// TI - Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors JO - Bioorganic Med Chem Lett VL - 23 UR - https://doi.org/10.1016/j.bmcl.2012.11.111 DO - 10.1016/j.bmcl.2012.11.111 ID - Duveau2013 ER - TY - JOUR AU - Blay, J. -. Y. AU - von Mehren, M. PY - 2011 DA - 2011// TI - Nilotinib: a novel, selective tyrosine kinase inhibitor JO - Semin Oncol VL - 38 UR - https://doi.org/10.1053/j.seminoncol.2011.01.016 DO - 10.1053/j.seminoncol.2011.01.016 ID - Blay2011 ER - TY - JOUR AU - von Bubnoff, N. AU - Gorantla, S. H. P. AU - Kancha, R. K. AU - Lordick, F. AU - Peschel, C. AU - Duyster, J. PY - 2005 DA - 2005// TI - The systemic mastocytosis-specific activating cKit mutation D816V can be inhibited by the tyrosine kinase inhibitor AMN107 JO - Leukemia VL - 19 UR - https://doi.org/10.1038/sj.leu.2403887 DO - 10.1038/sj.leu.2403887 ID - von Bubnoff2005 ER - TY - JOUR AU - Dewaele, B. AU - Wasag, B. AU - Cools, J. AU - Sciot, R. AU - Prenen, H. AU - Vandenberghe, P. PY - 2008 DA - 2008// TI - Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-08-0533 DO - 10.1158/1078-0432.CCR-08-0533 ID - Dewaele2008 ER - TY - JOUR AU - Shah, N. P. AU - Lee, F. Y. AU - Luo, R. AU - Jiang, Y. AU - Donker, M. AU - Akin, C. PY - 2006 DA - 2006// TI - Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis JO - Blood VL - 108 UR - https://doi.org/10.1182/blood-2005-10-3969 DO - 10.1182/blood-2005-10-3969 ID - Shah2006 ER - TY - JOUR AU - Guo, T. AU - Hajdu, M. AU - Agaram, N. P. AU - Shinoda, H. AU - Veach, D. AU - Clarkson, B. D. PY - 2009 DA - 2009// TI - Mechanisms of sunitinib resistance in gastrointestinal stromal tumors harboring KIT AY502-3ins mutation: an in vitro mutagenesis screen for drug resistance JO - Clin Cancer Res VL - 15 UR - https://doi.org/10.1158/1078-0432.CCR-09-1315 DO - 10.1158/1078-0432.CCR-09-1315 ID - Guo2009 ER - TY - JOUR AU - Eiring, A. M. AU - Deininger, M. W. PY - 2014 DA - 2014// TI - Individualizing kinase-targeted cancer therapy: the paradigm of chronic myeloid leukemia JO - Genome Biol VL - 15 UR - https://doi.org/10.1186/s13059-014-0461-8 DO - 10.1186/s13059-014-0461-8 ID - Eiring2014 ER - TY - JOUR AU - Remsing Rix, L. L. AU - Rix, U. AU - Colinge, J. AU - Hantschel, O. AU - Bennett, K. L. AU - Stranzl, T. PY - 2009 DA - 2009// TI - Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells JO - Leukemia VL - 23 UR - https://doi.org/10.1038/leu.2008.334 DO - 10.1038/leu.2008.334 ID - Remsing Rix2009 ER - TY - JOUR AU - Gozgit, J. M. AU - Wong, M. J. AU - Wardwell, S. AU - Tyner, J. W. AU - Loriaux, M. M. AU - Mohemmad, Q. K. PY - 2011 DA - 2011// TI - Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies JO - Mol Cancer Ther VL - 10 UR - https://doi.org/10.1158/1535-7163.MCT-10-1044 DO - 10.1158/1535-7163.MCT-10-1044 ID - Gozgit2011 ER - TY - JOUR AU - Lierman, E. AU - Smits, S. AU - Cools, J. AU - Dewaele, B. AU - Debiec-Rychter, M. AU - Vandenberghe, P. PY - 2012 DA - 2012// TI - Ponatinib is active against imatinib-resistant mutants of FIP1L1-PDGFRA and KIT, and against FGFR1-derived fusion kinases JO - Leukemia VL - 26 UR - https://doi.org/10.1038/leu.2012.8 DO - 10.1038/leu.2012.8 ID - Lierman2012 ER - TY - JOUR AU - Rix, U. AU - Remsing Rix, L. L. AU - Terker, A. S. AU - Fernbach, N. V. AU - Hantschel, O. AU - Planyavsky, M. PY - 2010 DA - 2010// TI - A comprehensive target selectivity survey of the BCR-ABL kinase inhibitor INNO-406 by kinase profiling and chemical proteomics in chronic myeloid leukemia cells JO - Leukemia VL - 24 UR - https://doi.org/10.1038/leu.2009.228 DO - 10.1038/leu.2009.228 ID - Rix2010 ER - TY - JOUR AU - Zabriskie, M. S. AU - Eide, C. A. AU - Tantravahi, S. K. AU - Vellore, N. A. AU - Estrada, J. AU - Nicolini, F. E. PY - 2014 DA - 2014// TI - BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia JO - Cancer Cell VL - 26 UR - https://doi.org/10.1016/j.ccr.2014.07.006 DO - 10.1016/j.ccr.2014.07.006 ID - Zabriskie2014 ER - TY - JOUR AU - Hadzijusufovic, E. AU - Peter, B. AU - Herrmann, H. AU - Rülicke, T. AU - Cerny-Reiterer, S. AU - Schuch, K. PY - 2012 DA - 2012// TI - NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation JO - Allergy VL - 67 UR - https://doi.org/10.1111/j.1398-9995.2012.02833.x DO - 10.1111/j.1398-9995.2012.02833.x ID - Hadzijusufovic2012 ER - TY - JOUR AU - Winter, G. E. AU - Rix, U. AU - Lissat, A. AU - Stukalov, A. AU - Mullner, M. K. AU - Bennett, K. L. PY - 2011 DA - 2011// TI - An integrated chemical biology approach identifies specific vulnerability of Ewing’s sarcoma to combined inhibition of Aurora kinases A and B JO - Mol Cancer Ther VL - 10 UR - https://doi.org/10.1158/1535-7163.MCT-11-0100 DO - 10.1158/1535-7163.MCT-11-0100 ID - Winter2011 ER - TY - JOUR AU - Zhang, J. AU - Adrián, F. J. AU - Jahnke, W. AU - Cowan-Jacob, S. W. AU - Li, A. G. AU - Iacob, R. E. PY - 2010 DA - 2010// TI - Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors JO - Nature VL - 463 UR - https://doi.org/10.1038/nature08675 DO - 10.1038/nature08675 ID - Zhang2010 ER - TY - STD TI - Reynolds CR, Islam SA, Sternberg MJE. EzMol: a web server wizard for the rapid visualisation and image production of protein and nucleic acid structures. J Mol Biol. 2018:1–5. https://doi.org/10.1016/j.jmb.2018.01.013. ID - ref88 ER -